These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25367453)

  • 1. Imaging cardiac amyloidosis: an opportunity for nuclear cardiology.
    Dorbala S
    J Nucl Cardiol; 2014 Dec; 21(6):1043-4. PubMed ID: 25367453
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular Imaging of Cardiac Amyloidosis.
    Pelletier-Galarneau M; Abikhzer G; Giraldeau G; Harel F
    Curr Cardiol Rep; 2019 Feb; 21(3):12. PubMed ID: 30815746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Nuclear Medicine and Molecular Imaging in the Diagnosis of Cardiomyopathy.
    Yang M; Arsanjani R; Roarke MC
    AJR Am J Roentgenol; 2020 Nov; 215(5):1208-1217. PubMed ID: 32901569
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular Imaging of Cardiac Amyloidosis.
    Masri A; Bukhari S; Eisele YS; Soman P
    J Nucl Med; 2020 Jul; 61(7):965-970. PubMed ID: 32482792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study.
    Law WP; Wang WY; Moore PT; Mollee PN; Ng AC
    J Nucl Med; 2016 Nov; 57(11):1733-1739. PubMed ID: 27307344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shining a Radiant Light on Cardiac Amyloidosis With Novel
    Pelletier-Galarneau M; Dilsizian V
    JACC Cardiovasc Imaging; 2023 Nov; 16(11):1449-1451. PubMed ID: 37940324
    [No Abstract]   [Full Text] [Related]  

  • 7. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization.
    Dorbala S; Ando Y; Bokhari S; Dispenzieri A; Falk RH; Ferrari VA; Fontana M; Gheysens O; Gillmore JD; Glaudemans AWJM; Hanna MA; Hazenberg BPC; Kristen AV; Kwong RY; Maurer MS; Merlini G; Miller EJ; Moon JC; Murthy VL; Quarta CC; Rapezzi C; Ruberg FL; Shah SJ; Slart RHJA; Verberne HJ; Bourque JM
    J Card Fail; 2019 Nov; 25(11):854-865. PubMed ID: 31473267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging.
    Dorbala S; Ando Y; Bokhari S; Dispenzieri A; Falk RH; Ferrari VA; Fontana M; Gheysens O; Gillmore JD; Glaudemans AWJM; Hanna MA; Hazenberg BPC; Kristen AV; Kwong RY; Maurer MS; Merlini G; Miller EJ; Moon JC; Murthy VL; Quarta CC; Rapezzi C; Ruberg FL; Shah SJ; Slart RHJA; Verberne HJ; Bourque JM
    J Card Fail; 2019 Nov; 25(11):e1-e39. PubMed ID: 31473268
    [No Abstract]   [Full Text] [Related]  

  • 9. Nuclear imaging modalities for cardiac amyloidosis.
    Bokhari S; Shahzad R; Castaño A; Maurer MS
    J Nucl Cardiol; 2014 Feb; 21(1):175-84. PubMed ID: 24162886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art.
    Popescu C; Burger IA
    Curr Radiopharm; 2021; 14(3):228-241. PubMed ID: 32525789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 18F-flutemetamol PET/CT able to reveal cardiac amyloidosis?
    Lhommel R; Sempoux C; Ivanoiu A; Michaux L; Gerber B
    Clin Nucl Med; 2014 Aug; 39(8):747-9. PubMed ID: 24978329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular phenotyping of infiltrative cardiomyopathies: The future.
    Dorbala S; Shaw LJ
    J Nucl Cardiol; 2019 Feb; 26(1):154-157. PubMed ID: 30535918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal pulmonary
    Pittman S; Sethi P; Flavell RR; De Marco T; Hernandez Pampaloni M
    J Nucl Cardiol; 2018 Oct; 25(5):1865-1868. PubMed ID: 29101671
    [No Abstract]   [Full Text] [Related]  

  • 14. Imaging of myocardial fatty acid metabolism with PET.
    Bergmann SR
    J Nucl Cardiol; 2007; 14(3 Suppl):S118-24. PubMed ID: 17556179
    [No Abstract]   [Full Text] [Related]  

  • 15. Serial scanning with technetium pyrophosphate (
    Castaño A; DeLuca A; Weinberg R; Pozniakoff T; Blaner WS; Pirmohamed A; Bettencourt B; Gollob J; Karsten V; Vest JA; Chiuzan C; Maurer MS; Bokhari S
    J Nucl Cardiol; 2016 Dec; 23(6):1355-1363. PubMed ID: 26453570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of Myocardial Enhancement on Cine-MRI: Diagnostic Value in Cardiac Amyloidosis.
    Cholet C; Damy T; Legou F; Kobeiter H; Rahmouni A; Deux JF
    Acad Radiol; 2019 Jun; 26(6):e98-e107. PubMed ID: 30072291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imagine, believe, and achieve.
    Peix A; Padrón K
    J Nucl Cardiol; 2021 Jun; 28(3):831-834. PubMed ID: 33963494
    [No Abstract]   [Full Text] [Related]  

  • 18. The diagnostic challenge of cardiomyopathies: When should we suspect cardiac amyloidosis?
    Gobbo M; Bender D; Mosto H; Sueiro H; Mocskos A; Tepper R; Carbajales J
    J Nucl Cardiol; 2020 Oct; 27(5):1844-1849. PubMed ID: 31659698
    [No Abstract]   [Full Text] [Related]  

  • 19. Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations.
    Ishida Y; Yoshinaga K; Miyagawa M; Moroi M; Kondoh C; Kiso K; Kumita S
    Ann Nucl Med; 2014 May; 28(4):393-403. PubMed ID: 24464391
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical molecular imaging with PET agents other than 18F-FDG.
    Hall LT; Struck AF; Perlman SB
    Curr Pharm Biotechnol; 2010 Sep; 11(6):545-54. PubMed ID: 20420567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.